AR047742A1 - Compuestos con actividad antitumoral - Google Patents
Compuestos con actividad antitumoralInfo
- Publication number
- AR047742A1 AR047742A1 ARP050100510A ARP050100510A AR047742A1 AR 047742 A1 AR047742 A1 AR 047742A1 AR P050100510 A ARP050100510 A AR P050100510A AR P050100510 A ARP050100510 A AR P050100510A AR 047742 A1 AR047742 A1 AR 047742A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- branched
- saturated
- hydrogen
- linear
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: El uso de un compuesto de formula general: X+-CH2-C(Z)H-CH2-Y-, caracterizado porque X+ se selecciona entre el grupo que consiste en N+(R1, R2, R3) y P+(R1, R2, R3), donde R1, R2 y R3, que son el mismo o diferentes, se seleccionan entre el grupo que consiste en hidrogeno y grupos alquilo C1-9 lineales o ramificados, -CH=NH(NH2), -NH2, -OH; o dos o más de R1, R2 y R3, junto con el átomo de nitrogeno al cual están unidos, forman un sistema heterocíclico monocíclico o bicíclico saturado o insaturado; con la salvedad que por lo menos uno de R1, R2 y R3 sea diferente de hidrogeno; Z se selecciona entre: -OR4; -OCOOR4; -OCONHR4; -OCSNHR4; -OCSOR4; -NHR4; -NHCOR4; -NHCSR4; -NHCOOR4; -NHCSOR4; -NHCONHR4; -NHCSNHR4; -NHSOR4; - NHSONHR4; -NHSO2R4; -NHSO2NHR4; -SR4; donde R4 es un grupo alquilo C2-20 saturado o insaturado, lineal o ramificado; Y- se selecciona entre el grupo que consiste en -COO-, -PO3H-, -OPO3H-, tetraazolato-5-ilo; sales, enantiomeros y mezcla racémicas de los mismos, para la preparacion de un medicamento antitumoral. Reivindicacion 4: El uso de acuerdo con la reivindicacion 3, caracterizado porque es del compuesto R-4-trimetilamonio-3-(tetradecilcarbamoil)aminobutirato. Reivindicacion 8: Una preparacion de acuerdo con la reivindicacion 7, caracterizada porque la antraciclina es doxorrubicina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000230A ITMI20040230A1 (it) | 2004-02-12 | 2004-02-12 | Composti ad attivita' antitumorale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047742A1 true AR047742A1 (es) | 2006-02-15 |
Family
ID=34856910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100510A AR047742A1 (es) | 2004-02-12 | 2005-02-11 | Compuestos con actividad antitumoral |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7652066B2 (es) |
| EP (1) | EP1713461B1 (es) |
| JP (1) | JP2007522165A (es) |
| KR (1) | KR101220331B1 (es) |
| CN (1) | CN1917867B (es) |
| AR (1) | AR047742A1 (es) |
| AT (1) | ATE476973T1 (es) |
| AU (1) | AU2005211906B2 (es) |
| BR (1) | BRPI0507664A (es) |
| CA (1) | CA2556069C (es) |
| CY (1) | CY1111048T1 (es) |
| DE (1) | DE602005022828D1 (es) |
| DK (1) | DK1713461T3 (es) |
| ES (1) | ES2350695T3 (es) |
| HK (1) | HK1099687A1 (es) |
| IT (1) | ITMI20040230A1 (es) |
| PL (1) | PL1713461T3 (es) |
| SI (1) | SI1713461T1 (es) |
| TW (1) | TWI361802B (es) |
| WO (1) | WO2005077354A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314144B2 (en) * | 2004-02-12 | 2012-11-20 | Defiante Farmaceutica, S.A. | Compounds having antitumor activity |
| WO2008109991A1 (en) | 2007-03-09 | 2008-09-18 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| WO2009015485A1 (en) | 2007-08-01 | 2009-02-05 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| ES2507089T3 (es) * | 2008-04-29 | 2014-10-14 | F. Hoffmann-La Roche Ag | Derivados del ácido 4-dimetilaminobutírico |
| WO2010008473A1 (en) * | 2008-06-24 | 2010-01-21 | Dara Biosciences, Inc. | Enzyme inhibitors and the use thereof |
| JP5746988B2 (ja) * | 2012-02-15 | 2015-07-08 | ライオン株式会社 | カプセル皮膜及びカプセル |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1299266B1 (it) | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
| AU784495B2 (en) * | 1999-11-12 | 2006-04-13 | Johns Hopkins University School Of Medicine, The | Treating cancer by increasing intracellular malonyl coa levels |
-
2004
- 2004-02-12 IT IT000230A patent/ITMI20040230A1/it unknown
-
2005
- 2005-02-05 TW TW094103976A patent/TWI361802B/zh not_active IP Right Cessation
- 2005-02-08 US US10/585,972 patent/US7652066B2/en not_active Expired - Fee Related
- 2005-02-08 CA CA2556069A patent/CA2556069C/en not_active Expired - Fee Related
- 2005-02-08 SI SI200531145T patent/SI1713461T1/sl unknown
- 2005-02-08 WO PCT/EP2005/001257 patent/WO2005077354A1/en not_active Application Discontinuation
- 2005-02-08 AT AT05707260T patent/ATE476973T1/de active
- 2005-02-08 AU AU2005211906A patent/AU2005211906B2/en not_active Ceased
- 2005-02-08 BR BRPI0507664-1A patent/BRPI0507664A/pt not_active IP Right Cessation
- 2005-02-08 JP JP2006552526A patent/JP2007522165A/ja not_active Ceased
- 2005-02-08 CN CN2005800046288A patent/CN1917867B/zh not_active Expired - Fee Related
- 2005-02-08 DE DE602005022828T patent/DE602005022828D1/de active Active
- 2005-02-08 PL PL05707260T patent/PL1713461T3/pl unknown
- 2005-02-08 KR KR1020067015984A patent/KR101220331B1/ko not_active IP Right Cessation
- 2005-02-08 ES ES05707260T patent/ES2350695T3/es active Active
- 2005-02-08 DK DK05707260.5T patent/DK1713461T3/da active
- 2005-02-08 EP EP05707260A patent/EP1713461B1/en active Active
- 2005-02-11 AR ARP050100510A patent/AR047742A1/es not_active Application Discontinuation
-
2007
- 2007-05-29 HK HK07105653.0A patent/HK1099687A1/xx not_active IP Right Cessation
-
2010
- 2010-11-03 CY CY20101100990T patent/CY1111048T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1713461A1 (en) | 2006-10-25 |
| DE602005022828D1 (de) | 2010-09-23 |
| JP2007522165A (ja) | 2007-08-09 |
| KR20060134059A (ko) | 2006-12-27 |
| WO2005077354A1 (en) | 2005-08-25 |
| ITMI20040230A1 (it) | 2004-05-12 |
| CA2556069C (en) | 2013-04-23 |
| TW200530154A (en) | 2005-09-16 |
| KR101220331B1 (ko) | 2013-01-09 |
| EP1713461B1 (en) | 2010-08-11 |
| ES2350695T3 (es) | 2011-01-26 |
| SI1713461T1 (sl) | 2010-12-31 |
| PL1713461T3 (pl) | 2011-01-31 |
| BRPI0507664A (pt) | 2007-07-17 |
| AU2005211906B2 (en) | 2009-07-30 |
| CN1917867A (zh) | 2007-02-21 |
| TWI361802B (en) | 2012-04-11 |
| HK1099687A1 (en) | 2007-08-24 |
| US20080227683A1 (en) | 2008-09-18 |
| ATE476973T1 (de) | 2010-08-15 |
| US7652066B2 (en) | 2010-01-26 |
| CA2556069A1 (en) | 2005-08-25 |
| CN1917867B (zh) | 2011-03-16 |
| AU2005211906A1 (en) | 2005-08-25 |
| DK1713461T3 (da) | 2010-11-22 |
| CY1111048T1 (el) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2475484C2 (ru) | Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака | |
| AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| CO6321289A2 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| AR057325A1 (es) | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos | |
| AR047742A1 (es) | Compuestos con actividad antitumoral | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR060768A1 (es) | Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| AR064842A1 (es) | Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| BRPI0507312A (pt) | derivados de quinolina para uso como inibidores micobacterianos | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| RU2008130887A (ru) | Водорастворимое соединение бензоазепина и содержащая его фармацевтическая композиция | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |